RESTYLANE EYELIGHT is trusted to deliver high patient satisfaction, with clinical results which demonstrating that 6.5 months after the first treatment, 88.6% of people reported looking less tired and 91.4% of people still felt attractive due to the improvement in their dark circles.1 In addition, 94.3% of people who tried RESTYLANE EYELIGHT would recommend it to a friend and repeat treatment.1
Lack of volume and volume loss in the under-eye region can create shadows and emphasize dark circles, leading to the appearance of tiredness and/or aging. In Europe, research has indicated that 66% of people are bothered by their under-eye circles.
RESTYLANE EYELIGHT contains hyaluronic acid which is part of Galderma’s proprietary NASHA gel technology. This is combined with lidocaine, a local anesthetic, to allow for a more comfortable treatment.
RESTYLANE® launched as the first non-animal stabilized HA filler in aesthetics. As a trusted and premium brand for 25 years, it has a proven track record in delivering effective treatment. Over the decades, 50 million RESTYLANE treatments have been administered across the globe.7
“We are excited to finally be bringing this product to market in the UK at ACE 2022. We will have lots of exciting Eyelight activity on the stand so please come and talk t us” Jo Neal, Restylane and Sculptra Brand Manager.
Data on file – (MA-48305).
Data on file – data submitted for publication (Consensus).
Verpaele A, Strand A. Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid- and lower face. Aesthetic Surgery Journal. 2006 Jan;26(1):S10–7.
Stutman RL, Codner MA. Tear Trough Deformity: Review of Anatomy and Treatment Options. Aesthetic Surgery Journal. 2012 May 1;32(4):426–40.
Data on file (MA-46075). European market survey by Opticom and Galderma Q4, 2020
Data on File – (MA39680) Restylane 50 million treatments
Data on file (MA-47865). Summary of Restylane Publications Analysis